drugset / Trial / NCT05473806
Effects of Pioglitazone and Evogliptin on Hepatic Fibrosis in Patients With Chronic Hepatitis B With Type 2 Diabetes
RandomizedParallel-groupOpen-labelTreatment
Summary
An exploratory comparison of changes in liver fibrosis through glycemic control within and between groups after administration of Pioglitazone and Evogliptin in chronic hepatitis B patients with type 2 diabetes and liver fibrosis
Timeline
- Start
- 2020-09-18
- Primary completion
- 2023-01-19
- Completion
- 2023-02-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Evogliptin | Small molecule | 5 mg | Oral |
| Subject | Pioglitazone | Small molecule | 15 mg | Oral |